Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer

1 Jun 2022

Abstract excerpt

autologous T cells that had been genetically engineered to clonally express two allogeneic HLA-C*08:02-restricted T-cell receptors (TCRs) targeting mutant KRAS G12D expressed by the tumors. The patient had regression of visceral metastases (overall partial response of 72% according to the Response Evaluation Criteria in Solid Tumors, version 1.1); the response was ongoing at 6 months. The engineered T cells...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Cancer Research and Treatments
Share to CAR-T cell therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35648703
DOI: 10.1056/nejmoa2119662

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neoantigen T-Cell Receptor Gene Therapy in Pancreatic CancerPMID 35648703Read ↗

More T cell receptors to the RAScue in cancer?Semantic proximity Read ↗

T cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trial.Semantic proximity Read ↗

Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients.Semantic proximity Read ↗

Adoptive transfer of T lymphocytes retrovirally transduced to express personalized neoantigen reactive T cell receptors can mediate tumor regression in patients with metastatic colorectal cancerSemantic proximity Read ↗

Targeting KRASG12V mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors.Semantic proximity Read ↗

Adoptive T-Cell Therapy in Solid Tumor with KRASG12V/G12D MutationSemantic proximity Read ↗

Expansion of KRAS hotspot mutations reactive T cells from human pancreatic tumors using autologous T cells as the antigen-presenting cells.Semantic proximity Read ↗

KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumorsSemantic proximity Read ↗

Recombinant T cell receptors specific for HLA-A*02:01-restricted neoepitopes containing KRAS codon 12 hotspot mutationsSemantic proximity Read ↗

Expansion of KRAS hot spot mutations reactive T cells from human pancreatic tumors using autologous T-cells as the antigen-presenting cellsSemantic proximity Read ↗

Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors.Semantic proximity Read ↗

IND-Enabling Studies for a TCR-T Targeting a Pancreatic Cancer KRASG12V MutationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.